Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels BERKELEY, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies
View HTML
Toggle Summary Dynavax Reports First Quarter 2018 Financial Results
Update on Initial Progress of HEPLISAV-B ® Commercial Launch Conference Call to be Held at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the first quarter ended March 31, 2018 .
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , May 07, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the “Committee”) approved the grant of inducement stock options to purchase an aggregate of 79,000
View HTML
Toggle Summary Dynavax to Host First Quarter 2018 Financial Results Conference Call
BERKELEY, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018 , and host a conference call that day to review the results
View HTML
Toggle Summary Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
HEPLISAV-B Now Meets a Critical Reimbursement Requirement for Many Insurance Plans BERKELEY, Calif. , April 23, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention (CDC) published the Advisory Committee of
View HTML
Toggle Summary Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR BERKELEY, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today
View HTML
Toggle Summary Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck
BERKELEY, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® , an anti-PD-1 therapy developed by Merck (known as
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 29, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of (i) inducement stock options to purchase an aggregate 114,000 shares of common
View HTML
Toggle Summary Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data from an ongoing Phase 1b/2 study
View HTML
Toggle Summary Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
HEPLISAV-B Launched in the United States Phase 2 Data in Two Immuno-oncology Programs Planned for First Half 2018 BERKELEY, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the fourth quarter and year ended December 31,
View HTML